🔍 Researchers have developed a method to optimize lentiviral vector (LV) production, allowing for high-titer LV harvest for more than 10 days. 💉 Using less cytotoxic transfection reagents and transfecting human embryonic kidney cells, they achieved high titers of up to 10^9 TU/mL. 💥 This method could improve the efficiency of gene therapy production. 🧬
📢 Revolutionary Method Extends High-Titer LV Production
Introduction:
Gene therapies are on the rise, and optimizing the production of lentiviral vectors (LV) is crucial for their success. However, current production methods are limited in terms of time and resources. Researchers in the UK have developed a method to overcome this limitation and produce high-titer LV for more than 10 days using traditional culture conditions.
Main points:
- The researchers compared three transfection reagents (Fugene®6, Genejuice®, and polyethyleneimine) for their ability to generate high-titer lentivirus vectors beyond the typical 72-hour lifespan of the cells.
- Genejuice® was found to be the most successful, with cell viability only five percent below that of untreated cells. LV harvest was possible for 15 days, producing up to 10^9 TU/mL.
- Coating the plasticware used for culture with Poly-2-hydroxyethyl methacrylate contributed to high cell viability in suspension cultures, reaching 3×10^8 TU/mL.
Conclusion:
This research presents a promising method for optimizing lentiviral vector production. The use of transfection reagents such as Genejuice® and the application of suspension cultures can lead to higher titers and longer production periods. Further development and scale-up of this method could significantly improve the efficiency of gene therapies.
